Dutch science-based company Royal DSM has unveiled its new ‘Maxilact Super’ lactase enzyme to produce lactose-free and sugar-reduced dairy products.

According to the Dutch firm, Maxilact Super is suitable for all lactose-free dairy products from regular to organic.

The latest offering will enable lactose-free dairy producers to deliver ‘health appeal and sensory experience’, which customers expect across all applications, the company claims.

DSM noted that Maxilact Super enzyme breaks down ‘lactose into its sweeter forms’, reducing the sugar levels in products effectively to as much as 20%.

The company added that the enzyme can reduce hydrolysis time during production by 33%, which helps in achieving efficiency in production.

The enzyme is also free from invertase and arylsulfatase, stated DSM.

DSM Milk Global Business Manager Ben Rutten stated: “With 71% of consumers checking the labels of the products they purchase3, combined with the ever-growing preference for lactose-free dairy and the sugar reduction trend that is here to stay, it is clear that prioritising health and authenticity is more important than ever for individuals today.

“DSM understands the challenges these diverse needs create for lactose-free dairy manufacturers, and with the innovative Maxilact Super solution – made possible thanks to more than 50 years of experience in lactase development and manufacturing – producers across the globe can efficiently deliver high-quality sugar-reduced and lactose-free dairy with next-generation consumer appeal.”

In February, DSM agreed to acquire the global human milk oligosaccharides (HMO) supplier Glycom for €765 ($827m).